drugset / Trial / NCT06027853
Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 target CAR iPSC NK cells in patients with relapsed/refractory AML
Timeline
- Start
- 2023-09-10
- Primary completion
- 2026-08-31
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLL1 CAR-NK cell injection | Cell therapy | — | — |
| Background | Cyclophosphamid | Unknown | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |